Molecular Mechanism of Asthma

NCT ID: NCT00180726

Last Updated: 2019-05-09

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: NA
• Study Classification: INTERVENTIONAL
• Study Start Date: 2003-12-31
• Study Completion Date: 2007-07-31

Brief Summary

The aim of this study is to investigate the mechanisms whereby lung function is decreased in asthma and sensitivity to treatment. The hypothesis is that in diseases such as asthma, inflammatory cells (leukocytes) including eosinophils, macrophages and lymphocytes migrate to the lung and release either more or different types of inflammatory mediators and/or receptors compared to subjects without asthma, which are corticoid sensitive or insensitive. The objective of the study is to identify which genes are specifically expressed in important cells in patients with asthma with a view to identify novel targets for drug therapy.

Detailed Description

We aim to investigate these separate cell types in the blood of subjects with asthma and identify which genes are more highly expressed when compared to cells obtained from patients without asthma. We will investigate corticosteroid sensitivity on gene expression in asthma (corticoid naive to corticosteroid resistant asthma). We will also investigate the lung cells (macrophages) from these subjects to identify whether the same or different genes are expressed in these cells.

We will isolate different leukocyte populations from the blood and extract ribonucleic acid (RNA) from these samples. The type and quantity of RNA in these samples is a reflection of the specific genes expressed in these cells. Gene expression is also evaluated by ELISA.This RNA will be sent to Gene Logic in the USA and this company will test these samples to identify which genes have been expressed using Gene Arrays. This technique will examine the expression of all 33,000 human genes in each sample to examine activation of interacting pathways rather than individual genes at a time. Samples will be analysed in the USA and preliminary data shows that there are no problems involving sample transportation or degradation.

Similar experiments will be performed using cells (macrophages) obtained following bronchoalveolar lavage of these subjects. We would aim to examine the responses of cells from two groups of subjects, namely (i) non-asthmatics controls and (ii) asthmatic subjects. The isolated cells will either be immediately solubilized in solutions to purify RNA or we will then use these isolated cells in vitro and following stimulation investigate whether different genes are expressed or at a differential rate in the disease state. We will examine both cells derived from peripheral blood and cells (macrophages) obtained from bronchoalveolar lavage with the aim to determine whether differences attributable to disease can be identified in both circulating cells and those at the site of disease.

This is a preliminary study to determine the profile of inflammatory mediator expression from leukocytes and as such power calculations to determine the number of subjects is not appropriate.

The objective of the study is to identify which genes are specifically expressed in important cells in patients with asthma with a view to identify novel targets for drug therapy.

Conditions

Asthma

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Interventions

Blood sampling, Endoscopic Bronchoscopy, Spirometry

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

Asthmatic Patients

1. Stable asthmatics on beta-2 agonist alone not using more than 4 puffs per day

2. Atopic as defined by positive skin prick tests to at least 2 common aeroallergens

3. PC20 methacholine of < 4 mg /ml

4. Increase in FEV1 > 15% following beta-2 agonist inhalation, either at the time of study or previously documented

5. Age 21-55 years of both sexes (females will be taking adequate contraceptive measures)

6. Non-smokers

7. Normal chest x-ray (CXR) and electrocardiogram (ECG) within the last 6 months.

Healthy Non-Asthmatic Subjects

All normal volunteers will meet the following criteria:

1. Age 21-70 years of both sexes (females will be taking adequate contraceptive measures)

2. No history of respiratory or allergic disease e.g. PC20 methacholine of > 64mg/ml and negative skin prick tests

3. Non-atopic with negative skin prick tests to common aeroallergens

4. Normal baseline spirometry as predicted for age, sex and height.

5. Non-smokers

6. Not taking regular medication

7. No upper respiratory tract infection within the last 6 weeks

Exclusion Criteria

1. Clinically significant findings in the medical history or on physical examination other than those of asthma in the asthma group.

2. Lung function FEV1 <30%

3. Pregnant women or mothers who are breastfeeding.

4. Patients who smoke

5. Upper respiratory infection within the last 4 weeks

6. Allergy to local anaesthetic

7. Subjects who are unable to give informed consent.

• Minimum Eligible Age: 21 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Imperial College London

OTHER

Sponsor Role: lead

Principal Investigators

Ian M Adcock, PhD

Role: PRINCIPAL_INVESTIGATOR

NHLI, Imperial College

Locations

Airway Disease, NHLI, Imperial College

London, , United Kingdom

Countries

United Kingdom

Other Identifiers

NHLI-MB-1

Identifier Type: -

Identifier Source: org_study_id